EMVERM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emverm, and when can generic versions of Emverm launch?
Emverm is a drug marketed by Impax Labs Inc and is included in one NDA.
The generic ingredient in EMVERM is mebendazole. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mebendazole profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMVERM?
- What are the global sales for EMVERM?
- What is Average Wholesale Price for EMVERM?
Summary for EMVERM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 142 |
| Patent Applications: | 3,581 |
| Drug Prices: | Drug price information for EMVERM |
| DailyMed Link: | EMVERM at DailyMed |
Pharmacology for EMVERM
| Drug Class | Anthelmintic |
US Patents and Regulatory Information for EMVERM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax Labs Inc | EMVERM | mebendazole | TABLET, CHEWABLE;ORAL | 073580-001 | Jan 4, 1995 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
